2019年美国肾脏病学会肾脏周:阿斯利康展示关键的roxadustat III期数据

2019-10-31 Allan MedSci原创

阿斯利康表示,III期临床计划在非透析依赖型(NDD)或透析依赖型(DD)患者中使用roxadustat 治疗慢性肾脏病(CKD),进而对roxadustat进行有效性和心血管安全性分析。

阿斯利康表示,III临床计划在非透析依赖型(NDD)或透析依赖型(DD)患者中使用roxadustat 治疗慢性肾脏病(CKD),进而对roxadustat进行有效性和心血管安全性分析。这些数据将在2019115日至10日在美国华盛顿特区举行的美国肾脏病学会(ASN)肾脏周上展示。汇总的有效性和安全性分析增加了关于roxadustat(一种新型的缺氧诱导因子脯氨酰羟化酶抑制剂)的证据。

慢性肾脏病(又称慢性肾功能不全或慢性肾衰竭),指肾功能在几个月或若干年期间逐渐而难以逆转的衰退。据估计,慢性肾病患者占美国成年人口的13%


原始出处:

http://www.firstwordpharma.com/node/1677457#axzz63qZhPxYq

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2010654, encodeId=b703201065407, content=<a href='/topic/show?id=691282e17c1' target=_blank style='color:#2F92EE;'>#肾脏病学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82717, encryptionId=691282e17c1, topicName=肾脏病学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sun Jul 26 07:57:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916185, encodeId=af811916185b3, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jun 08 04:57:00 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080266, encodeId=49d2208026656, content=<a href='/topic/show?id=0f1de9881ec' target=_blank style='color:#2F92EE;'>#美国肾脏病学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79881, encryptionId=0f1de9881ec, topicName=美国肾脏病学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Sat Jul 04 09:57:00 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548121, encodeId=766815481212a, content=<a href='/topic/show?id=f9d315653b0' target=_blank style='color:#2F92EE;'>#roxadustat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15653, encryptionId=f9d315653b0, topicName=roxadustat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Nov 02 01:57:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594666, encodeId=0c021594666d7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 02 01:57:00 CST 2019, time=2019-11-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2010654, encodeId=b703201065407, content=<a href='/topic/show?id=691282e17c1' target=_blank style='color:#2F92EE;'>#肾脏病学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82717, encryptionId=691282e17c1, topicName=肾脏病学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sun Jul 26 07:57:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916185, encodeId=af811916185b3, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jun 08 04:57:00 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080266, encodeId=49d2208026656, content=<a href='/topic/show?id=0f1de9881ec' target=_blank style='color:#2F92EE;'>#美国肾脏病学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79881, encryptionId=0f1de9881ec, topicName=美国肾脏病学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Sat Jul 04 09:57:00 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548121, encodeId=766815481212a, content=<a href='/topic/show?id=f9d315653b0' target=_blank style='color:#2F92EE;'>#roxadustat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15653, encryptionId=f9d315653b0, topicName=roxadustat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Nov 02 01:57:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594666, encodeId=0c021594666d7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 02 01:57:00 CST 2019, time=2019-11-02, status=1, ipAttribution=)]
    2020-06-08 juliusluan78
  3. [GetPortalCommentsPageByObjectIdResponse(id=2010654, encodeId=b703201065407, content=<a href='/topic/show?id=691282e17c1' target=_blank style='color:#2F92EE;'>#肾脏病学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82717, encryptionId=691282e17c1, topicName=肾脏病学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sun Jul 26 07:57:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916185, encodeId=af811916185b3, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jun 08 04:57:00 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080266, encodeId=49d2208026656, content=<a href='/topic/show?id=0f1de9881ec' target=_blank style='color:#2F92EE;'>#美国肾脏病学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79881, encryptionId=0f1de9881ec, topicName=美国肾脏病学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Sat Jul 04 09:57:00 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548121, encodeId=766815481212a, content=<a href='/topic/show?id=f9d315653b0' target=_blank style='color:#2F92EE;'>#roxadustat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15653, encryptionId=f9d315653b0, topicName=roxadustat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Nov 02 01:57:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594666, encodeId=0c021594666d7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 02 01:57:00 CST 2019, time=2019-11-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2010654, encodeId=b703201065407, content=<a href='/topic/show?id=691282e17c1' target=_blank style='color:#2F92EE;'>#肾脏病学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82717, encryptionId=691282e17c1, topicName=肾脏病学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sun Jul 26 07:57:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916185, encodeId=af811916185b3, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jun 08 04:57:00 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080266, encodeId=49d2208026656, content=<a href='/topic/show?id=0f1de9881ec' target=_blank style='color:#2F92EE;'>#美国肾脏病学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79881, encryptionId=0f1de9881ec, topicName=美国肾脏病学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Sat Jul 04 09:57:00 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548121, encodeId=766815481212a, content=<a href='/topic/show?id=f9d315653b0' target=_blank style='color:#2F92EE;'>#roxadustat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15653, encryptionId=f9d315653b0, topicName=roxadustat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Nov 02 01:57:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594666, encodeId=0c021594666d7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 02 01:57:00 CST 2019, time=2019-11-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2010654, encodeId=b703201065407, content=<a href='/topic/show?id=691282e17c1' target=_blank style='color:#2F92EE;'>#肾脏病学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82717, encryptionId=691282e17c1, topicName=肾脏病学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sun Jul 26 07:57:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916185, encodeId=af811916185b3, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jun 08 04:57:00 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080266, encodeId=49d2208026656, content=<a href='/topic/show?id=0f1de9881ec' target=_blank style='color:#2F92EE;'>#美国肾脏病学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79881, encryptionId=0f1de9881ec, topicName=美国肾脏病学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Sat Jul 04 09:57:00 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548121, encodeId=766815481212a, content=<a href='/topic/show?id=f9d315653b0' target=_blank style='color:#2F92EE;'>#roxadustat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15653, encryptionId=f9d315653b0, topicName=roxadustat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Nov 02 01:57:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594666, encodeId=0c021594666d7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 02 01:57:00 CST 2019, time=2019-11-02, status=1, ipAttribution=)]

相关资讯

阿斯利康宣布在京建立北部总部 深化在华全面战略布局

近日,全球领先的生物制药企业阿斯利康宣布将在北京经济技术开发区建立中国北部总部,此举意味着阿斯利康将通过开启区域总部的模式进一步深化其在中国的全局化战略布局,对未来形成中国多总部的格局具有里程碑式的重要意义。北京市政府副秘书长杨秀玲,北京经济技术开发区工委书记王少峰,阿斯利康全球首席执行官苏博科,阿斯利康中国副总裁、企业事务及市场准入部负责人黄彬均出席和见证了战略签约仪式。

阿斯利康的SGLT2抑制剂达格列嗪治疗心力衰竭获得FDA的快速通道认证

阿斯利康宣布,美国食品和药物管理局为其每日口服一次的SGLT2抑制剂Farxiga(达格列嗪)授予快速通道认证,以降低射血分数保留的心力衰竭(HFpEF)和射血分数下降的心力衰竭(HFrEF的)心血管(CV)死亡风险或恶化分数。阿斯利康生物制药研发部门负责人Mene Pangalos评论说:"我们期待与FDA合作,探索Farxiga作为心力衰竭患者的潜在新治疗方案。"

2019欧洲心脏病学会ESC:阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功

阿斯利康AstraZeneca宣布其糖尿病治疗药物Farxiga在DAPA-HF临床试验中治疗心力衰竭取得成功,结果显示射血分数降低(HFrEF)。

精简管线!阿斯利康放弃与和黄医药合作开发Savolitinib肾癌3期研究

阿斯利康放弃与和黄医药合作开发savolitinib(沃利替尼) 作为乳头状肾细胞癌(PRCC)单一疗法的后期临床试验。这项临床3期研究是阿斯利康从今年第二季度开始精简研发管线策略中的五个项目之一。

阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险

该公司周一报道,FDA批准阿斯利康的Farxiga(dapagliflozin)降低2型糖尿病和已确定的心血管(CV)疾病或多种CV危险因素的成年人因心力衰竭住院的风险。

阿斯利康9500万美元购买优先审评券,哪项研发项目可能获益?

今日,阿斯利康(AstraZeneca)宣布,以9500万美元的价格从瑞典一家公司Sobi收购了一张FDA优先审评劵。优先审评劵可将新药申请的审批时间从10个月缩短到6个月,从而大大加速新药的上市进程。